<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="112460">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01687166</url>
  </required_header>
  <id_info>
    <org_study_id>CDM00048665</org_study_id>
    <nct_id>NCT01687166</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of the Blazer Open-Irrigated Ablation Catheter for the Treatment of Paroxysmal Atrial Fibrillation</brief_title>
  <acronym>ZERO-AF</acronym>
  <official_title>Clinical Evaluation of the Blazer Open-Irrigated Ablation Catheter for the Treatment of Paroxysmal Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish the safety and effectiveness of the Blazer
      Open-Irrigated radiofrequency ablation catheter for the treatment of drug refractory,
      recurrent, symptomatic, paroxysmal atrial fibrillation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ZERO-AF trial is a prospective, multicenter, single blind, 1:1 randomized study. The
      trial is designed to demonstrate that the safety and effectiveness of the Blazer®
      Open-Irrigated Ablation Catheter are non-inferior to the safety and effectiveness of the
      control catheters, for the treatment drug refractory, recurrent, symptomatic, paroxysmal
      atrial fibrillation. The control catheters are open-irrigated radiofrequency ablation
      catheters that are approved in the United States for the treatment of drug refractory
      recurrent symptomatic paroxysmal atrial fibrillation, when used with compatible
      three-dimensional electroanatomic mapping systems.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Procedure-related complication free rate</measure>
    <time_frame>7-days post-index procedure</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The safety of the Blazer OI catheter will be evaluated by demonstrating that the investigational group serious adverse event rate is non-inferior to that of the control group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Procedure-related complication free rate (continued)</measure>
    <time_frame>Within 12 months of the index procedure</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The safety of the Blazer OI catheter will be evaluated by demonstrating that the investigational group rate of significant pulmonary vein stenosis (≥70% reduction in diameter from baseline) and atrio-esophageal fistulas is non-inferior to that of the control group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Chronic success rate</measure>
    <time_frame>Within 12 months of the index procedure</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary effectiveness of the Blazer OI catheter will be evaluated by demonstrating that the proportion of subjects free from failure* in the investigational group is non-inferior to those in the control group.
*failure is defined as a randomized subject being an acute procedural failure, having more than one repeat procedure during the 90 day blanking period or having a documented symptomatic atrial fibrillation, atrial tachycardia, atrial fibrillation between 91 days and 12 months post-procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Success</measure>
    <time_frame>20 minutes after the last radiofrequency application to isolate the pulmonary vein</time_frame>
    <safety_issue>No</safety_issue>
    <description>Demonstration that the investigational group acute procedural success rate is non-inferior to that of the control group. Acute procedural success is defined as a subject that successfully had all clinically relevant veins electrically isolated, by demonstration of entrance block at a minimum and no evidence of exit conduction with the randomized investigational or control catheter only.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">472</enrollment>
  <condition>Paroxysmal Atrial Fibrillation (PAF)</condition>
  <arm_group>
    <arm_group_label>Blazer Open-Irrigated Ablation Catheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blazer Open-Irrigated Ablation Catheter and Ablation Catheter Cable used in conjunction with a compatible electroanatomic mapping system</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FDA Approved Open-Irrigated Ablation Catheter</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FDA approved Open-Irrigated Radiofrequency Ablation Catheter system and compatible electroanatomic mapping system for the treatment of paroxysmal atrial fibrillation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Blazer Open-Irrigated Ablation Catheter (Boston Scientific)</intervention_name>
    <arm_group_label>Blazer Open-Irrigated Ablation Catheter</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FDA Approved Open-Irrigated Ablation Catheter</intervention_name>
    <arm_group_label>FDA Approved Open-Irrigated Ablation Catheter</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of recurrent symptomatic PAF with ≥2 episodes reported within   the 365 days
             prior to enrollment

             o PAF is AF episodes that last ≥30 seconds in duration and terminate within 7 days.

          -  At least 1 episode of PAF documented by Holter monitor, rhythm strip,
             trans-telephonic monitor (TTM), or 12-lead ECG in the 365 days prior to enrollment

          -  Refractory to at least one Beta Blocker, Calcium Channel Blocker, Class I OR Class
             III anti-arrhythmic drug (AAD)

          -  Age 18 or above, or of legal age to give informed consent specific to state and
             national law

          -  Competent and willing to provide written informed consent to participate in the study
             and agree to comply with follow-up visits and evaluation

        Exclusion Criteria:

          -  Have any of the following heart conditions within 90 days prior to enrollment:

               -  New York Heart Association (NYHA) Class III or IV

               -  Left ventricular ejection fraction (LVEF) &lt;35%

               -  Left atrial (LA) diameter &gt;5.5 cm

               -  Unstable angina or ongoing myocardial ischemia

               -  Transmural myocardial infarction (MI)

          -  Congenital structural heart disease that increases the risk of ablation or precludes
             catheter placement

          -  Undergone any left atrial catheter or surgical ablation

          -  Have had a coronary intervention, cardiac surgery, or other cardiac ablation within
             90 days prior to enrollment

          -  Had &gt;1 AF episode lasting greater than 7 days, with no episodes having lasted greater
             than 30 days, within the past year

          -  Subjects regularly prescribed amiodarone therapy during the 120 days prior to
             enrollment

          -  Contraindication to anticoagulation therapy

          -  Creatinine &gt;2.5mg/dl or creatinine clearance &lt;30mL/min within 90 days (3 months)
             prior to enrollment

          -  Prosthetic mitral or tricuspid heart valves

          -  Confirmed cardiac thrombus within 30 days (1 month) prior to enrollment

          -  Implanted pacemaker, ICD, or CRT leads within 180 days (6 months) prior to enrollment

          -  History of CVA, TIA or PE within 180 days (6 months) prior to enrollment

          -  Left atrial appendage closure device

          -  Any other significant uncontrolled or unstable medical condition (e.g. sepsis, acute
             metabolic illness, end stage COPD)

          -  Enrolled in any concurrent clinical trial without documented pre-approval from BSC

          -  Women who are pregnant or plan to become pregnant within the course of their
             participation in the investigation

          -  Life expectancy ≤ 2 years (730 days) per physician opinion
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Natale, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Cardiac Arrhythmia Institute at St. David's Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bryan Wylie</last_name>
    <phone>(408) 935-6166</phone>
    <email>bryan.wylie@bsci.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lynnett Voshage-Stahl</last_name>
    <phone>651-582-2994</phone>
    <email>Lynnett.Voshage-Stahl@bsci.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Sydes, MPH, RN</last_name>
      <email>ksydes@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Tom McElderry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vance Plumb, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gourg Atteya</last_name>
      <phone>203-737-1330</phone>
      <email>gourg.atteya@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Jude Clancy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paige Smith</last_name>
      <email>pfsmith@emory.edu</email>
    </contact>
    <investigator>
      <last_name>David B DeLurgio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mikhael El-Chami, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgia Health Sciences University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Anne Park, RN, MSN</last_name>
      <phone>706-721-0193</phone>
      <email>mpark@gru.edu</email>
    </contact>
    <investigator>
      <last_name>William Maddox, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patti Naismith</last_name>
      <phone>248-898-8141</phone>
      <email>pnaismith@beaumont.edu</email>
    </contact>
    <investigator>
      <last_name>David Haines, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jersey Shore University Medical Center</name>
      <address>
        <city>Neptune</city>
        <state>New Jersey</state>
        <zip>07754</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Samu-Arce</last_name>
      <phone>732-776-3884</phone>
      <email>ssamu@meridianhealth.com</email>
    </contact>
    <investigator>
      <last_name>Charles Koo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ashish Patel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Kuznekoff</last_name>
      <phone>212-263-7704</phone>
      <email>Laura.Kuznekoff@nyumc.org</email>
    </contact>
    <investigator>
      <last_name>Larry Chinitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anthony Aizer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mt. Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Betsy Ellsworth, MSN, ANP</last_name>
      <phone>212-824-8902</phone>
      <email>betsy.ellsworth@mountsinai.org</email>
    </contact>
    <investigator>
      <last_name>Jacob Koruth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vivek Reddy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Strong Memorial Hospital of the University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Wing, RN</last_name>
      <email>laura_wing@urmc.rochester.edu</email>
    </contact>
    <investigator>
      <last_name>David Huang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Burr Hall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Medical Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cassie Ramm, RN</last_name>
      <phone>919-843-1610</phone>
      <email>cassandra_ramm@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Mounsey, PhD, FACC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eugene Chung, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Akron General Medical Center</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Ryan, RN</last_name>
      <email>julie.ryan@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>John Hummel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Kalbfleish, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Phuong</last_name>
      <phone>215-615-0186</phone>
      <email>David.Phuong@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Gregory Supple, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbie Adams, RN</last_name>
      <email>adamsde@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Frank Cuoco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>J.Lacy Sturdivant, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Cardiac Arrhythmia Research Foundation</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deb Cardinal</last_name>
      <email>dscardinal@austinheartbeat.com</email>
    </contact>
    <investigator>
      <last_name>David Burkhardt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shane Bailey, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>G J Gallinghouse, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amin Al-Ahmad, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Pierce, RN, MBA</last_name>
      <phone>713-704-4137</phone>
      <email>Mary.H.Pierce@uth.tmc.edu</email>
    </contact>
    <investigator>
      <last_name>Ramesh Hariharan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Saumya Sharma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Trinity Mother of Frances Health System</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Cushman</last_name>
      <phone>903-510-8846</phone>
      <email>cushmac@tmfhs.org</email>
    </contact>
    <investigator>
      <last_name>Stanislav Weiner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Sims, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlotesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mary Jane Strickland</last_name>
      <email>Mjs7w@virginia.edu</email>
    </contact>
    <investigator>
      <last_name>J. Michael Mangrum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heart Care Partners</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>QL 4120 QLD</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Estelle Beevors</last_name>
      <phone>+61 7 3858 8697</phone>
      <email>ebeevors@heartcarepartners.com.au</email>
    </contact>
    <investigator>
      <last_name>Karen Phillips, FRACP, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julie Humphries, FRACP, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>SA 5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanessa Maxwell</last_name>
      <phone>+61 8 8222 2003</phone>
      <email>mailto:vanessa.maxwell@adelaide.edu.au</email>
    </contact>
    <investigator>
      <last_name>Prash Sanders, FRACP, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Hospital de Santa Cruz</name>
      <address>
        <city>Carnaxide</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Adragao, MD</last_name>
      <email>padragao@netcabo.pt</email>
    </contact>
    <contact_backup>
      <last_name>Ricardo A Domingues Bernardo</last_name>
      <email>rb914942329@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Pedro Adragão, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diogo Cavaco, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pedro Carmo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <state>Huddinge</state>
        <zip>SE-141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Ersgard</last_name>
      <email>'david.ersgard@ki.se'</email>
    </contact>
    <investigator>
      <last_name>Jonas Schwieler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Australia</country>
    <country>Portugal</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>March 30, 2014</lastchanged_date>
  <firstreceived_date>August 29, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Paroxysmal Atrial Fibrillation</keyword>
  <keyword>Cardiac Arrhythmias</keyword>
  <keyword>Heart Disease</keyword>
  <keyword>Cardiovascular Disease</keyword>
  <keyword>Radiofrequency Ablation</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acifluorfen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
